Novel intravitreal fluocinolone acetonide implant in the treatment of chronic noninfectious posterior uveitis

References

• Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: Fundamentals and Clinical Practice. (2nd Ed.). Mosby, MO, USA (1996).
   Google Scholar
• Foster CS, Vitale AT. Treatment of uveitis: overview. In: Diagnosis and Treatment of Uveitis. (1st Ed.). WB Saunders Company, NY, USA, 150 (2002).
   Google Scholar
• Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br. J. Ophthalmol.88, 1159–1162 (2004).
   PubMed Web of Science ®Google Scholar
• Gritz DC, Wong IG. Incidence and prevalence of uveitis in northern California; the northern California epidemiology of uveitis study. Ophthalmology111(3), 491–500 (2004).
   PubMed Web of Science ®Google Scholar
• Dandona L, Dandona R, John RK et al. Population based assessment of uveitis in an urban population in southern India. Br. J. Ophthalmol.84, 706–709 (2000).
   PubMed Web of Science ®Google Scholar
• Becker MD, Smith JR, Max R, Feihn C. Management of sight-threatening uveitis: new therapeutic options. Drugs65(4), 497–519 (2005).
   PubMed Web of Science ®Google Scholar
• Rothova A. Corticosteroids in uveitis. Ophthalmol. Clin. North Am.15(3), 389–394 (2002).
   PubMedGoogle Scholar
• Jabs DA, Rosenbaum JT, Foster CS et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol.130, 492–513 (2000).
   PubMed Web of Science ®Google Scholar
• Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest. Ophthalmol. Vis. Sci.41(5), 961–964 (2000).
   PubMed Web of Science ®Google Scholar
• Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina24, 676–698 (2004).
   PubMed Web of Science ®Google Scholar
• Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am. J. Ophthalmol.141, 629–637 (2006).
   PubMed Web of Science ®Google Scholar
• Quiram PA, Gonzales CR, Schwartz SD. Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol.141, 580–582 (2006).
   PubMed Web of Science ®Google Scholar
• Yang CS, Chen MJ, Chou CK, Hsu WM. Refractory severe ocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmologica219, 413–415 (2005).
   PubMedGoogle Scholar
• Jonas JB, Spandau UH, Kamppeter BA et al. Follow-up after intravitreal triamcinolone acetonide for diabetic macular edema. Eur. J. Ophthalmol.16, 566–572 (2006).
   PubMedGoogle Scholar
• Kok H, Lau C, Maycock N et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology112, 1916 (2005).
   PubMed Web of Science ®Google Scholar
• Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology111(5), 960–965 (2004).
   PubMed Web of Science ®Google Scholar
• Goldstein DA, Fontanilla FA, Kaul S et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology109(2), 370–377 (2002).
   PubMed Web of Science ®Google Scholar
• Sarwal MM, Yorgin PD, Alexander S et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation72(1), 13–21 (2001).
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum.46(2), 328–346 (2002).
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology108(6), 1134–1139 (2001).
   PubMed Web of Science ®Google Scholar
• Doycheva DG, Deuter CM, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br. J. Ophthalmol. doi:10.1136/bjo.2006.094698 (2006). (Epub ahead of print).
   Google Scholar
• Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin. Experiment. Ophthalmol.31(6), 487–491 (2003).
   PubMed Web of Science ®Google Scholar
• Siepmann K, Huber M, Stubiger N, Deuter C, Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch. Clin. Exp. Ophthalmol.244, 788–794 (2006).
   PubMed Web of Science ®Google Scholar
• Thorne JE, Jabs DA, Qazi FA, Nguyen QD, Kempen JH, Dunn JP. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology112, 1472–1477 (2005).
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, de Smet MD, Rubin B et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am. J. Ophthalmol.115, 583–591 (1993).
   PubMedGoogle Scholar
• Hesselink DA, Baarsma GS, Kuijpers RW et al. Experience with cyclosporine in endogenous uveitis posterior. Transplant Proc.36(2), 372S–377S (2004).
   PubMed Web of Science ®Google Scholar
• Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocular Immunol. Inflamm.13, 335–351 (2005).
   PubMed Web of Science ®Google Scholar
• Caspi RR. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int. Rev. Immunol.21(2–3), 197–208 (2002).
   PubMedGoogle Scholar
• Nussenblatt RB, Thompson DJ, Li Z et al. Humanized anti-interleukin-2 (IL-2) receptor α therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J. Autoimmun.21(3), 283–293 (2003).
   PubMed Web of Science ®Google Scholar
• Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology110(4), 786–789 (2003).
   PubMed Web of Science ®Google Scholar
• Church AC. Clinical advances in therapies targeting the interleukin-2 receptor. QJM96(2), 91–102 (2003).
   PubMed Web of Science ®Google Scholar
• Santos LM, Marcos MC, Gallardo GJM et al. Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic Res.33(5), 251–255 (2001).
   PubMed Web of Science ®Google Scholar
• Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis (letter). Arthritis Rheum.48(7), 2079–2080 (2003).
   PubMedGoogle Scholar
• Etanercept Prescribing Information. Immunex Corp.; Amgen; Wyeth (2006).
   Google Scholar
• Suhler EB, Smith JR, Wertheim MS et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch. Ophthalmol.123, 903–912 (2005).
   PubMed Web of Science ®Google Scholar
• Infliximab Prescribing Information. Centocor, Inc., PA, USA (2006).
   Google Scholar
• Murphy CC, Greiner K, Plskova J et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch. Ophthalmol.122, 845–851 (2004).
   PubMed Web of Science ®Google Scholar
• Kim H, Robinson MR, Lizak MJ et al. Controlled drug release from an ocular implant: an evaluation using dynamic 3-dimensional magnetic resonance imaging. Invest. Ophthalmol. Vis. Sci.45(8), 2722–2731 (2004).
   PubMed Web of Science ®Google Scholar
• Kurz D, Ciulla TA. Novel approaches for retinal drug delivery. Ophthalmol. Clin. North Am.15(3), 405–410 (2002).
   PubMedGoogle Scholar
• Retisert™ Prescribing Information, Bausch & Lomb, Inc. (2005).
   Google Scholar
• Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest. Ophthalmol. Vis. Sci.41(11), 3569–3575 (2000).
   PubMed Web of Science ®Google Scholar
• Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J. Ocul. Pharmacol. Therapeutics20(3), 269–275 (2004).
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology112, 1192–1198 (2005).
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis. Ophthalmology113, 1019–1026 (2006).
   PubMedGoogle Scholar
• Lim LL, Smith JR, Rosenbaum JT. Retisert: Bausch and Lomb/Control Delivery Systems. Curr. Opin. Invest. Drugs6(11), 1159–1167 (2005).
   PubMedGoogle Scholar
• Fluocinolone acetonide ophthalmic – Bausch & Lomb: fluocinolone acetonide envision TD implant. Drugs RD6(2), 116–119 (2005).
   PubMedGoogle Scholar
• Herbert HM, Viswanathan A, Jackson H, Lightman SL. Risk factors for elevated intraocular pressure in uveitis. J. Glaucoma13, 96–99 (2004).
   PubMed Web of Science ®Google Scholar
• Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am. J. Ophthalmol.139, 421–428 (2005).
   PubMed Web of Science ®Google Scholar
• Bucher RS, Hall E, Reed DM, Richards JE, Johnson MW, Zacks DN. Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment. Arch. Ophthalmol.123(5), 649–653 (2005).
   PubMedGoogle Scholar